{"id":"NCT01091662","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic","officialTitle":"Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2012-11","completion":"2012-11","firstPosted":"2010-03-24","resultsPosted":"2015-12-21","lastUpdate":"2016-10-24"},"enrollment":172,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Eslicarbazepine acetate 1600 mg","otherNames":[]},{"type":"DRUG","name":"Eslicarbazepine acetate 1200 mg","otherNames":[]}],"arms":[{"label":"eslicarbazepine acetate 1600 mg","type":"EXPERIMENTAL"},{"label":"eslicarbazepine acetate 1200 mg","type":"EXPERIMENTAL"}],"summary":"This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy.","primaryOutcome":{"measure":"Cumulative 112-day Exit Rate as Estimated by Kaplan-Meier Method","timeFrame":"From beginning of Week 3 to end of Week 18","effectByArm":[{"arm":"ESL1200 mg","deltaMin":0.156,"sd":null},{"arm":"ESL 1600 mg","deltaMin":0.128,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":12},"locations":{"siteCount":62,"countries":["United States","Bulgaria","Czechia","Serbia","Ukraine"]},"refs":{"pmids":["25880756"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":58},"commonTop":["Headache","Dizziness","Nausea","Nasopharyngitis","Solmnolence"]}}